<DOC>
	<DOC>NCT00346827</DOC>
	<brief_summary>To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.</brief_summary>
	<brief_title>Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Apomorphine</mesh_term>
	<criteria>1 year history of Parkinson's Disease; stable PD medications for 4 weeks; at least one documented "off" period per day hypersensitivity to apomorphine; participation in a clinical trial in the last 12 weeks; pregnant or lactating females</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2006</verification_date>
</DOC>